Search for: "Doe v. Mylan Pharmaceuticals, Inc." Results 1 - 20 of 163
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
27 Jul 2018, 6:00 am by Kyle Kroll
Mylan Pharmaceuticals, Inc., 18-1638 (Fed. [read post]
3 May 2016, 9:00 pm by Dennis Crouch
  Their practices emphasize pharmaceutical patent counseling, patent procurement, and patent litigation. [2] Acorda Therapeutics Inc. et al. v. [read post]
16 Jun 2019, 9:30 pm by Patent Docs
Mylan Pharmaceuticals Inc.), held that State sovereign immunity does not preclude institution of inter partes review proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. [read post]
1 Oct 2022, 2:31 pm by Lawrence B. Ebert
The outcome: Mylan Pharmaceuticals Inc. [read post]
27 Jul 2018, 6:00 am by Kyle Kroll
Mylan Pharmaceuticals, Inc., 18-1638 (Fed. [read post]
21 Feb 2019, 8:45 am by Lawrence B. Ebert
Mylan Pharmaceuticals Inc., No. 2018-2097 (“Valeant II”), Salix moves todisqualify in Salix Pharmaceuticals, Inc. v. [read post]
23 Jul 2018, 2:38 pm by Jason Rantanen
Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., AKORN, Inc. [read post]